Overview

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

Status:
COMPLETED
Trial end date:
2025-06-03
Target enrollment:
Participant gender:
Summary
Phase I Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
Phase:
PHASE1
Details
Lead Sponsor:
Cascade Pharmaceuticals, Inc